Form 4: Director Jonathan Lim Receives Stock Options at Maze

Director Jonathan E. Lim was granted 18,000 stock options in Maze Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Jonathan E. Lim received a grant of 18,000 stock options on June 8, 2026.
• The options have an exercise price of $23.58 per share.
• The options are scheduled to vest on the earlier of the 2027 annual stockholders meeting or June 8, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Granting of options results in potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon the reporting person's continued service to the issuer.

Future Outlook

The options vest in one year, contingent on continued service, reflecting standard director retention practices.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 8, 2027, or the 2027 annual stockholders meeting.

Key Dates

Keywords

Maze Therapeutics, MAZE, Form 4, Insider Trading, Stock Options, Director Compensation